Smith CC - Search Results

1

Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.

Lasater EA, Massi ES, Stecula A, Politi J, Tan SK, Smith CC, Gunthorpe M, Holmes JP, Chehab F, Sali A, Shah NP. Lasater EA, et al. Among authors: smith cc. Leukemia. 2016 Jun;30(6):1405-9. doi: 10.1038/leu.2015.303. Epub 2015 Oct 29. Leukemia. 2016. PMID: 26511402 No abstract available.

2

Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.

Smith CC, Shah NP. Smith CC, et al. Clin Cancer Res. 2011 Nov 1;17(21):6605-7. doi: 10.1158/1078-0432.CCR-11-2240. Epub 2011 Sep 26. Clin Cancer Res. 2011. PMID: 21948230

3

Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.

Smith CC, Shah NP. Smith CC, et al. Hematology Am Soc Hematol Educ Program. 2011;2011:121-7. doi: 10.1182/asheducation-2011.1.121. Hematology Am Soc Hematol Educ Program. 2011. PMID: 22160023 Review.

4

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Smith CC, et al. Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016. Nature. 2012. PMID: 22504184 Free PMC article.

5

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Smith CC, et al. Blood. 2013 Apr 18;121(16):3165-71. doi: 10.1182/blood-2012-07-442871. Epub 2013 Feb 21. Blood. 2013. PMID: 23430109 Free PMC article.

6

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.

Smith CC, Shah NP. Smith CC, et al. Am Soc Clin Oncol Educ Book. 2013:313-8. doi: 10.14694/EdBook_AM.2013.33.313. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714533 Free article. Review.

7

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Verstovsek S, et al. Among authors: smith cc. Leuk Res. 2014 Mar;38(3):316-22. doi: 10.1016/j.leukres.2013.12.006. Epub 2013 Dec 11. Leuk Res. 2014. PMID: 24374145 Free PMC article. Clinical Trial.

8

Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia.

Smith CC, Shah NP. Smith CC, et al. Am Soc Clin Oncol Educ Book. 2012:685-9. doi: 10.14694/EdBook_AM.2012.32.103. Am Soc Clin Oncol Educ Book. 2012. PMID: 24451819 Free article.

9

Crenolanib is a selective type I pan-FLT3 inhibitor.

Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Smith CC, et al. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. doi: 10.1073/pnas.1320661111. Epub 2014 Mar 12. Proc Natl Acad Sci U S A. 2014. PMID: 24623852 Free PMC article.

10

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.

Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. Warkentin AA, et al. Among authors: smith cc. Elife. 2014 Dec 22;3:e03445. doi: 10.7554/eLife.03445. Elife. 2014. PMID: 25531068 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

683 results

Search Page